Axiom Investors LLC Bei Gene, Ltd. Transaction History

Axiom Investors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$158.67 - $201.58 $594,060 - $754,715	-3,744 Reduced 4.27%	83,985 $15.1 Million
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $7.46 Million - $9.34 Million	-41,490 Reduced 32.11%	87,729 $15.8 Million
Q2 2023 Aug 10, 2023	SELL	$178.3 - $266.78 $6.5 Million - $9.73 Million	-36,457 Reduced 22.0%	129,219 $23 Million
Q1 2023 May 12, 2023	BUY	$215.53 - $274.5 $35.7 Million - $45.5 Million	165,676 New	165,676 $35.7 Million

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Axiom Investors LLC , based on Form 13F filings with the SEC.

Stay updated on Axiom Investors LLC with notifications on news.